CEMIP and familial pancreatic carcinoma: Combination of CA 19-9 with CEMIP showed markedly improved AUROC over that of CA 19-9 alone in the diagnosis of pancreatic cancer against healthy individuals (AUROC, 0.94 vs. 0.88; P < 0.0001) (Fig. 2B).